Dr Kathryn Skelding

Dr Kathryn Skelding

Senior Lecturer

School of Biomedical Sciences and Pharmacy (Medical Biochemistry)

Cells, signalling and cancer therapies

From an early age, Dr Kathryn Skelding was fascinated by how the body works, and this focus continues to drive her desire to understand how diseases develop and how they can be treated.

A molecular biologist with expertise in cell biology, Kathryn believes that if we can understand the processes of cancer cell proliferation, survival and the development of resistance to chemotherapeutics, we can develop new, targeted anti-cancer therapies.

An early career researcher with an expertise spanning from fundamental biochemistry to clinical evaluation of new anti-cancer therapeutics, Kathryn has already made important contributions to science. And it’s her innate curiosity that’s driven her work.

"I always wanted to know why – why does that disease develop? How does that treatment work?" Kathryn says.

"So it was just natural that I would become a medical researcher who investigates the causes of diseases, so that we can develop new and better treatments."  This curiosity continued throughout her undergraduate studies, where Kathryn graduated with first class Honours and the University Medal in Biomedical Science from UON.

The development of new targeted therapies for a varieties of cancer was an early theme of her research; Kathryn’s doctoral studies examined the use of novel oncolytic viruses as treatments for breast cancer, and were funded by a National Breast Cancer Foundation Scholarship. Phase I trials for these viruses showed that they were safe and well-tolerated, with evidence of disease stabilisation.

Kathryn’s choice of research field was greatly influenced by personal experience, as several people close to her have been affected by cancer. "While it's well-known that side effects are associated with chemotherapy, it's only when you actually see what these drugs do to someone that it really hits home how toxic they are," she says.

Her research is focussed on brain cancer, leukaemia, breast cancer and prostate cancer – but it is the first two topics that hold Kathryn’s strongest focus. “Both leukaemia and brain cancer are unique in that they have very poor outcomes that have remained unchanged for decades. Both diseases are still fairly under-researched and the survival rates have remained static – we need more research into these areas.”

Kathryn studies how cancer cells function so that she can better understand how cancer cells grow, spread and develop resistance to chemotherapy drugs. "If scientists can better understand these processes, we can develop new treatments for cancer that are more cancer-cell specific and have fewer side effects," she says.

Kathryn is exploring the role of targeting in regulating cancer cell proliferation, invasion and resistance to chemotherapy, exploring how novel inhibitors can play a role in targeting pathways. The aim is to develop new therapies and kill the cancer cells – with maximum effectiveness, while minimising side-effects.

Cell biology and leukaemia

With her leukaemia research, Kathryn’s team is focussed on a protein molecule called BAALC (brain and acute leukaemia, cytoplasmic), which is associated with aggressive disease that is more likely to recur, and also indicate that chemotherapeutic drugs may not be effective against these leukaemia cells. "My lab focuses on a molecule that is present in high amounts in leukaemia cells, and that we have shown is involved in controlling cancer cell growth and survival."

Kathryn has dedicated her attention to developing a new inhibitor for this molecule, and the results are promising. This inhibitor is currently being developed with Newcastle Innovation, a University of Newcastle company that bridges gaps between technology and commercial partners, with the aim of introducing these technologies into clinical use.

Working closely with her colleagues in the University's Priority Research Centre for Cancer, and through her association with the Hunter Medical Research Institute (HMRI) Kathryn has also established important links and relationships with clinical oncologists which continues to fuel her research.

Over her career, Kathryn has been successfully awarded funding from a broad range of bodies, which is vital to translating research findings into the clinic. With so many exciting outcomes in her early research career, Kathryn’s focussed research is bound to lead to treatments which can not only lead to improved patient outcomes – but a better quality of life.

Cells, signalling and cancer therapies

Dr Kathryn Skelding focusses on cancer cell biology, specifically how cancer cells proliferate, metastasise, and develop resistance to chemotherapeutics.

Read more

Career Summary

Biography

Dr Skelding is an early career researcher, who was appointed to a full-time continuing lecturing position at the start of 2012.  Her research focuses on understanding cancer cell biology, specifically how cancer cells proliferate, metastasise, and develop resistance to chemotherapeutics. If these processes can be better understood, new targeted anti-cancer therapies can be discovered.  Dr Skelding's PhD investigated the use of oncolytic viruses as novel anti-cancer agents, and was funded by a National Breast Cancer Foundation (NBCF) Scholarship, as well as the commercial company, Viralytics Ltd.

During her PhD, Dr Skelding developed new clinically relevant mouse models of spontaneously metastasising breast cancer, which allowed her to examine the pre-clinical effectiveness of novel viral therapies for cancer, both as single agents, and in combination with currently approved chemotherapeutic agents.

Additionally, the research undertaken throughout Dr Skelding's PhD has led to the commencement of a Phase II clinical trial in the use of this virus (CAVATAK) as an intravenous treatment for melanoma, breast, and prostate cancer. In her post-doctoral studies, Dr Skelding further applied her background in cell biology to examine signal transduction pathways and the role of targeting in regulating CaMKII (calcium/calmodulin-stimulated protein kinase II) function in neuronal cells.

Since completing her post-doctoral studies in 2012, she has established her own research group that focuses on better understanding cell signalling in cancer, with a view to developing new therapies that are cancer cell-specific and suitable for the treatment of a range of cancers, with a focus on leukaemias (specifically acute myeloid leukaemia, and childhood acute lymphoblastic leukaemia), breast cancer and prostate cancer. 

Dr Skelding has received several awards throughout her research career, including the International Society for Neurochemistry Travel Award (2011), Best Early Career Researcher Speaker at the Hunter Medical Research Institute Cancer Research Program Symposium (2010), Best Speaker at the University of Newcastle Graduate Student’s Day (2006), University Medal in Biomedical Science (2003), the University of Newcastle Vice Chancellor’s Award for Academic Excellence (2000), and numerous undergraduate and post-graduate training scholarships. Due to work completed throughout her PhD, the Hon Roslyn Kelly (Chair of the National Breast Cancer Foundation Board of Trustees) nominated Dr Skelding for a Fresh Science Award in 2006, for which she was short-listed.

Dr Skelding's overarching research aim is improve patient outcomes and quality of life, by translating her research findings into the clinic.

Research Expertise
Dr Skelding's research interests focus on examining signal transduction pathways and the role of targeting in regulating cancer cell proliferation, invasion/migration and chemotherapy resistance, so that new targets for controlling these cellular functions can be identified. Using a variety of molecular, biochemical and cellular techniques (including siRNA and overexpression transfection of cancer and normal cell lines, western blotting, immunoprecipitation, immunofluorescence, immunohistochemistry, proliferation assays, cell survival assays, flow cytometry, invasion and migration assays), she has identified new pathways involved in these processes. Additionally, she has developed novel inhibitors that can target these pathways. Dr Skelding is currently examining the efficacy of these new drugs in a range of cancer types, including acute myeloid and lymphoblastic leukaemia, breast cancer and prostate cancer.

Teaching Expertise
Cell biology Biochemistry Molecular biology

Administrative Expertise
Dr Skelding is a member of the University of Newcastle Faculty of Health Occupational Health and Safety Committee, and has been on the organising committee for several conferences and symposium days. Dr Skelding is also on the editorial board of the International Journal, Calcium Signalling.

Collaborations
Dr Skelding's interest in the regulation of protein function via targeting has led to her forming local, national, and international collaborations to investigate the role of protein phosphorylation in heart disease and following stroke, as well as investigating protein phosphatase 2A (PP2A) reactivators as new treatments for leukaemia and breast cancer.

Qualifications

  • PhD, University of Newcastle

Keywords

  • Anti-cancer drugs
  • Biochemistry
  • Brain cancer
  • Breast cancer
  • Cancer
  • Cancer cell biology
  • Cell cycle
  • Enzymes
  • Leukaemia
  • Molecular Targeting
  • Prostate cancer
  • Protein Phosphorylation
  • Proteins

Languages

  • English (Fluent)

Fields of Research

Code Description Percentage
060103 Cell Development, Proliferation and Death 25
111201 Cancer Cell Biology 50
111204 Cancer Therapy (excl. Chemotherapy and Radiation Therapy) 25

Professional Experience

UON Appointment

Title Organisation / Department
Senior Lecturer University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Academic appointment

Dates Title Organisation / Department
1/01/2013 -  Editorial Board - Calcium Signalling Calcium Signalling
Australia
1/01/2013 -  Membership - Australian Society of Biochemistry and Molecular Biology Australian Society of Biochemistry and Molecular Biology
Australia
1/01/2012 - 31/12/2015 Lecturer University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/07/2007 - 1/12/2011 Research Associate University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Membership

Dates Title Organisation / Department
1/01/2008 - 31/12/2014 Membership - Australian Neuroscience Society Australian Neuroscience Society (ANS)
Australia

Invitations

Speaker

Year Title / Rationale
2015 CaMKII – a new target for regulating breast cancer cell invasion and migration
Organisation: 8th Annual World Cancer Conference
2012 Progression through mitosis can be controlled by dephosphorylation of CaMKII at T253
Organisation: APSN and JSN Description: Invited presentation
2010 Importance of community support in performing medical research
Organisation: NBCF Description: Invited presentation
2007 Use of a common cold-producing virus as a potential treatment for breast cancer
Organisation: NBCF Description: Invited presentation
Edit

Grants and Funding

Summary

Number of grants 26
Total funding $1,704,555

Click on a grant title below to expand the full details for that specific grant.


20161 grants / $5,000

Equipment Grant: Developing Synthetic Exosomes to Target and Deliver Anti-Cancer Agents to Prostate Cancer$5,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Mr Joshua Brzozowski, Doctor Jude Weidenhofer, Doctor Kathryn Skelding, Associate Professor Christopher Scarlett
Scheme Project Grant
Role Investigator
Funding Start 2016
Funding Finish 2016
GNo G1601042
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20157 grants / $601,190

A novel biomarker for luminal B breast cancer$359,577

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Doctor Nikki Verrills, Doctor Kathryn Skelding
Scheme Research Grant
Role Investigator
Funding Start 2015
Funding Finish 2017
GNo G1400487
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Live cell imager for enhancement of pre-clinical cancer studies in the Hunter Translational Cancer Research Centre$124,938

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Conjoint Professor Stephen Ackland, Doctor Kelly Kiejda, Associate Professor Kevin Spring, Professor Xu Dong Zhang, Associate Professor Deborah Marsh, Associate Professor Christopher Scarlett, Doctor Pradeep Tanwar, Doctor Kathryn Skelding, Doctor Rick Thorne, Doctor Nikola Bowden
Scheme Research Equipment Grant
Role Investigator
Funding Start 2015
Funding Finish 2016
GNo G1500598
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Live cell imager for enhancement of pre-clinical cancer studies in the Hunter Translational Cancer Research Centre$25,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Stephen Ackland, Doctor Kelly Kiejda, Associate Professor Kevin Spring, Professor Xu Dong Zhang, Associate Professor Deborah Marsh, Associate Professor Christopher Scarlett, Doctor Pradeep Tanwar, Doctor Kathryn Skelding, Doctor Rick Thorne, Doctor Nikola Bowden
Scheme Equipment Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1500953
Type Of Funding Internal
Category INTE
UON Y

A novel approach to cancer therapy - targeting patients with loss of a specific tumour suppressor gene$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills, Doctor Kathryn Skelding
Scheme Project Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1501201
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Improving the effectiveness of a new treatment for acute myeloid leukaemia (AML)$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kathryn Skelding, Miss MENGNA Chi, Doctor Nikki Verrills, Doctor Roger Liang
Scheme Project Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1600224
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

BAALC - a novel target for the development of new treatments for brain cancer.$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kathryn Skelding, Doctor Craig Gedye
Scheme Project Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1600225
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Too Much of a Good Thing: Application for a triple-gas incubator to allow cell culture under normal conditions$16,675

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Craig Gedye, Laureate Professor Rodney Scott, Doctor Nikola Bowden, Associate Professor Simon Keely, Doctor Kathryn Skelding
Scheme Research Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1500730
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20147 grants / $832,699

Tetraspanin CD9; more than just an exosome marker - A novel biomarker to target for prostate cancer$400,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jude Weidenhofer, Doctor Kathryn Skelding, Doctor Matt Dun, Ms Belinda Goldie, Doctor Danielle Bond
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2017
GNo G1400921
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Identification of BAALC as a new target for the treatment of acute myeloid leukaemia$200,000

Funding body: Cancer Australia

Funding body Cancer Australia
Project Team Doctor Kathryn Skelding
Scheme Priority-driven Collaborative Cancer Research Scheme
Role Lead
Funding Start 2014
Funding Finish 2015
GNo G1300551
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Visualisation of microparticles for development of biomarkers and targeted drug delivery mechanisms$125,199

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Associate Professor Christopher Scarlett, Doctor Kathryn Skelding, Doctor Jude Weidenhofer, Doctor Matt Dun, Doctor Kelly Kiejda, Professor Adam McCluskey, Ms Elham Sadeqzadeh, Professor Hubert Hondermarck, Doctor Rick Thorne, Laureate Professor Rodney Scott
Scheme Research Equipment Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1400627
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Developing Synthetic Exosomes to Target and Deliver Anti-Cancer Agents to Prostate Cancer Cells$37,500

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Mr Joshua Brzozowski, Doctor Jude Weidenhofer, Doctor Kathryn Skelding
Scheme Postgraduate Research Scholarship
Role Investigator
Funding Start 2014
Funding Finish 2016
GNo G1401405
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Myr-C310: A new treatment for childhood leukaemia$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kathryn Skelding, Doctor Nikki Verrills
Scheme Project Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1301349
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Preclinical testing of a novel therapeutic strategy for breast cancer $25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills, Doctor Kathryn Skelding
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1301439
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Identification of BAALC as a new target for the treatment of acute myeloid leukaemia $20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Kathryn Skelding, Doctor Nikki Verrills
Scheme Near Miss Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1301404
Type Of Funding Internal
Category INTE
UON Y

20132 grants / $49,596

Targeting BAALC as a new treatment for acute myeloid leukaemia$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kathryn Skelding, Doctor Nikki Verrills
Scheme Project Grant
Role Lead
Funding Start 2013
Funding Finish 2013
GNo G1301348
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20123 grants / $55,570

Microscopic illumination system for advanced fluorescent protein technology$34,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Rick Thorne, Professor Xu Dong Zhang, Professor Murray Cairns, Doctor Nikki Verrills, Doctor Charles De Bock, Doctor Jude Weidenhofer, Doctor Severine Roselli, Doctor Kathryn Skelding, Emeritus Professor Leonie Ashman, Professor Hubert Hondermarck
Scheme Equipment Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1100983
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Regulation of the cell cycle by phosphorylation dependent targeting of CaMKII$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Nikki Verrills, Doctor Kathryn Skelding, Emeritus Professor John Rostas, Associate Professor Phillip Dickson, Conjoint Professor Keith Jones
Scheme Near Miss Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1200679
Type Of Funding Internal
Category INTE
UON Y

The 11th Biennial meeting of the Asian Pacific Society for Neurochemistry and the 55th Annual meeting of the Japanese Society for Neurochemistry, Kobe Conference Centre, 30 September - 2 October 2012$1,570

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Doctor Kathryn Skelding
Scheme Travel Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1201010
Type Of Funding Internal
Category INTE
UON Y

20113 grants / $63,200

Regulation of Breast Cancer Growth by a Novel Phosphorylation-Dependent Targeting Mechanism$35,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kathryn Skelding, Doctor Nikki Verrills, Emeritus Professor John Rostas
Scheme Breast Cancer Project Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1001005
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Role of CaMKII targeting in stroke susceptibility and outcome$18,200

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Emeritus Professor John Rostas, Professor Neil Spratt, Doctor Kathryn Skelding
Scheme Stroke Research Project Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1001013
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

IMPLEN NanoPhotometer pearl$10,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Murray Cairns, Associate Professor Paul Tooney, Professor Alan Brichta, Emeritus Professor John Rostas, Emeritus Professor Patricia Michie, Conjoint Professor Keith Jones, Professor Ulli Schall, Associate Professor Phillip Dickson, Associate Professor Rohan Walker, Doctor Rick Thorne, Associate Professor Chris Dayas, Doctor Nikki Verrills, Doctor Janet Bristow, Doctor Severine Roselli, Doctor Kathryn Skelding, Doctor Jude Weidenhofer, Associate Professor Liz Milward, Doctor Charles De Bock, Doctor Julie Merriman-Jones, Doctor Jing Qin Wu, Doctor Bing Liu, Dr DAN Johnstone, Ms Belinda Goldie, Doctor Natalie Beveridge
Scheme Equipment Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100030
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20101 grants / $34,000

ABI 7500 Real Time PCR System $34,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Rick Thorne, Doctor Nikki Verrills, Professor Murray Cairns, Associate Professor Paul Tooney, Associate Professor Doug Smith, Professor Gordon Burns, Emeritus Professor Leonie Ashman, Conjoint Professor Keith Jones, Doctor Charles De Bock, Associate Professor Chris Dayas, Associate Professor Brett Graham, Doctor Martin Horan, Doctor Rebecca Lim, Doctor Severine Roselli, Doctor Larisa Bobrovskaya, Doctor Kathryn Skelding, Associate Professor Rohan Walker, Doctor Jude Weidenhofer, Professor Philip Bolton, Professor Alan Brichta, Professor Robert Callister, Professor Trevor Day, Associate Professor Phillip Dickson, Professor Manohar Garg, Doctor Phil Jobling, Professor Derek Laver, Associate Professor Eugene Nalivaiko, Emeritus Professor John Rostas
Scheme Equipment Grant
Role Investigator
Funding Start 2010
Funding Finish 2010
GNo G1000055
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20091 grants / $1,700

The 22nd Biennial Meeting of the ISN/APSN Joint Meeting, Busan South Korea, 23-28 August 2009$1,700

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Doctor Kathryn Skelding
Scheme Travel Grant
Role Lead
Funding Start 2009
Funding Finish 2009
GNo G0190587
Type Of Funding Internal
Category INTE
UON Y

20051 grants / $61,600

Viral Oncolysis of Human Breast Cancer$61,600

Funding body: National Breast Cancer Foundation

Funding body National Breast Cancer Foundation
Project Team Doctor Kathryn Skelding
Scheme Postgraduate Research Scholarship
Role Lead
Funding Start 2005
Funding Finish 2005
GNo G0184441
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y
Edit

Research Supervision

Number of supervisions

Completed8
Current4

Total current UON EFTSL

PhD1.45

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2016 PhD BAALC ¿ A New Target for Controlling Survival of AML Cells PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2015 PhD PPP2R2A - A Novel Biomarker and Therapeutic Target for Luminal B Breast Cancer PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2014 PhD Identification of Biomarkers and Novel Targets for Prostate Cancer from Exosomes PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2014 PhD Developing Synthetic Exosomes to Target and Deliver Anti-Cancer Agents to Prostate Cancer Cells PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor

Past Supervision

Year Level of Study Research Title Program Supervisor Type
2016 Honours DNA repair in acute myeloid leukaemia Biochemistry & Cell Biology, UoN Principal Supervisor
2015 Honours BAALC over expression: a new mechanism controlling sensitivity to chemotherapeutic agents in acute myeloid leukaemia Biochemistry & Cell Biology, UoN Principal Supervisor
2014 Honours BAALC: A new target for the treatment of childhood leukaemia Biochemistry & Cell Biology, UoN Principal Supervisor
2013 Honours Role of tetraspanins in prostate cancer exosome functions Biochemistry & Cell Biology, UoN Co-Supervisor
2013 Masters Effects of Multi-site Phosphorylation on CaMKII Function M Philosophy (Medical Biochem), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2013 Honours PP2A reactivation as a new treatment for breast cancer Biochemistry & Cell Biology, UoN Co-Supervisor
2011 Honours The role of protein phosphatase 2A in FLT3+ leukaemia Biochemistry & Cell Biology, UoN Co-Supervisor
2010 Honours Controlling the cell cycle - the role of CaMKII Biochemistry & Cell Biology, UoN Co-Supervisor
Edit

News

Pablo Moscato small

Debunking myths about cancer

February 4, 2014

University of Newcastle researchers are debunking myths as they pave the way forward in cancer research.

Dr Kathryn Skelding

Position

Senior Lecturer
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Focus area

Medical Biochemistry

Contact Details

Email kathryn.skelding@newcastle.edu.au
Phone (02) 4921 5982
Fax (02) 4921 6903

Office

Room LS3-41
Building Life Sciences
Location Callaghan
University Drive
Callaghan, NSW 2308
Australia
Edit